Seattle Genetics, Inc. (NASDAQ:SGEN)

CAPS Rating: 3 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Recs

0
Player Avatar temujinkan (< 20) Submitted: 9/30/2010 2:06:04 PM : Outperform Start Price: $9.54 SGEN Score: +118.10

Buy this now!!

Report this Post Reply

Featured Broker Partners


Advertisement